PRNewsWire
10 Jul 2026, 00:57 UTC · 10w ago
Verdict
Headline leans bearish. We score IONS −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Ionis Pharmaceuticals' Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint of reducing combined cardiovascular death and recurrent events.
So whatThe failure of a Phase-3 trial for a major program typically results in a significant loss of future revenue potential and a sharp decline in valuation.
More negative than 99% of claims this week
The law firm Levi & Korsinsky has launched an investigation into whether Ionis made materially false or misleading statements regarding the CARDIO-TTRansform program.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 78% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company's Phase-3 CARDIO-TTRansform trial failed its primary endpoint, leading to a 20% stock price drop and a securities fraud investigation.
More negative than 74% of ticker scores this week
AstraZeneca was the partner in the failed Phase-3 CARDIO-TTRansform trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
6h ago
−28.8%
Price agrees with the score
$45.75 vs $64.27 close before publication (Jul 9) · not market-adjusted
IONS chart →
